HEDIS MEASURE



Adult Immunization Status (AIS-E)

By working together, we can improve health outcomes for your patients, our members. The Healthcare Effectiveness Data and Information Set (HEDIS®) helps us measure many aspects of performance. This tip sheet provides key details of the HEDIS measure for adult immunization status (AIS-E).

What Is the Measure?

The percentage of members 19 years of age and older who are up to date on recommended routine vaccines for influenza, tetanus and diphtheria (Td) or tetanus, diphtheria, and acellular pertussis (Tdap), zoster, pneumococcal, and hepatitis B.

Exclusions

- Members who use hospice services or elect to use a hospice benefit any time during the measurement year.
- Members who die any time during the measurement year.

Denominator

Eligible Population:

 Members 19 years and older at the start of the measurement period (January 1– December 31).

Numerator

Influenza

 Members who received an <u>influenza vaccine</u> on or between July 1 of the year prior to the measurement period and June 30 of the measurement period, *or* members with anaphylaxis due to the influenza vaccine any time before or during the measurement period.

Td/Tdap

- Members who received at least one <u>Td vaccine</u> or one <u>Tdap vaccine</u> between nine years prior to the start of the measurement period and the end of the measurement period, *or* members with a history of at least one of the following contraindications any time before or during the measurement period:
 - Anaphylaxis due to the diphtheria, tetanus, or pertussis vaccine
 - Encephalitis due to the diphtheria, tetanus, or pertussis vaccine

Continued next page

All summaries of the measures contained herein are reproduced with permission from MY 2025 HEDIS Volume 1: Technical Specifications for Health Plans by the National Committee for Quality Assurance (NCQA). HEDIS® is a registered trademark of the NCQA. Please see the final page of this document for the full copyright citation.

Florida Blue is an independent licensee of the Blue Cross and Blue Shield Association. 121129 0225

Zoster

Members who received two doses of the <u>herpes zoster</u> recombinant at least 28 days apart, on October 1, 2017, through the end of the measurement period, *or* members with anaphylaxis due to the herpes zoster vaccine any time before or during the measurement period.

Pneumococcal

 Members who received at least one dose of an adult <u>pneumococcal vaccine</u> on or after their 19th birthday, before or during the measurement period, *or* members with anaphylaxis due to the pneumococcal vaccine any time before or during the measurement period.

Hepatitis B

- Members who received at least three doses of the childhood <u>hepatitis B vaccine</u> with different dates of service on or before their 19th birthday.
 - One of the three vaccinations can be a newborn hepatitis B vaccination during the eight-day period that begins on the date of birth and ends seven days after the date of birth. For example, if the member's date of birth is December 1, the newborn hepatitis B vaccination must be on or between December 1 and December 8.
- Members who received a hepatitis B vaccine series on or after their 19th birthday, before or during the measurement period, including either of the following:
 - At least two doses of the recommended two-dose adult hepatitis B vaccine administered at least 28 days apart; or at least three doses of any other recommended adult hepatitis B vaccine administered on different days of service.
- Members who had a hepatitis B surface antigen, hepatitis B surface antibody, or total antibody to hepatitis B core antigen test, with a positive result any time before or during the measurement period. Any of the following meet criteria:
 - A test with a result greater than 10 mIU/mL.
 - A test with a finding of immunity.
- Members with a history of hepatitis B illness any time before or during the measurement period. Do not include laboratory claims.
- Members with anaphylaxis due to the hepatitis B vaccine any time before or during the measurement period.

Content reproduced with permission from HEDIS® MY2025, Volume 2: Technical Specifications for Health Plans by the National Committee for Quality Assurance (NCQA). HEDIS measures and specifications are not clinical guidelines and do not establish a standard of medical care. NCQA makes no representations, warranties, or endorsement about the quality of any organization or physician that uses or reports performance measures and NCQA has no liability to anyone who relies on such measures or specifications. Limited proprietary coding sets are contained in the specifications for convenience, and users should obtain all necessary licenses from the owners of the code sets. NCQA disclaims all liability for use or accuracy of any coding contained in the specifications. To purchase copies of the publication, including the full measures and specifications, visit ncqa.org/publications.